Dietary soybean protein ameliorates high-fat diet-induced obesity by modifying the gut microbiota-dependent biotransformation of bile acids

The consumption of soybean protein has well-known favorable metabolic effects (e.g., reduced body weight, body fat, hyperglycemia, insulin resistance, hepatic steatosis, and lipogenesis). These effects of soy protein have been linked to modulation by the gut microbiota; however, the dynamic interpla...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 13; no. 8; p. e0202083
Main Authors Watanabe, Keita, Igarashi, Miki, Li, Xuan, Nakatani, Akiho, Miyamoto, Junki, Inaba, Yuka, Sutou, Asuka, Saito, Tsutomu, Sato, Takumi, Tachibana, Nobuhiko, Inoue, Hiroshi, Kimura, Ikuo
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 13.08.2018
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The consumption of soybean protein has well-known favorable metabolic effects (e.g., reduced body weight, body fat, hyperglycemia, insulin resistance, hepatic steatosis, and lipogenesis). These effects of soy protein have been linked to modulation by the gut microbiota; however, the dynamic interplay among these factors remains unclear. Accordingly, we examined the metabolic phenotype, intestinal BA pool, and the gut microbiome of male C57BL/6 mice that were randomized to receive either a regular high-fat diet (HFD) or HFD that contained soybean protein isolate (SPI) in place of dairy protein. The intake of SPI significantly reduced the HFD-induced weight gain and adipose tissue mass accumulation and attenuated hepatic steatosis. Along with an enhancement in the secretion of intestinal Glucagon-like peptide-1 (GLP-1), an enlarged cecal BA pool with an elevated secondary/primary BA ratio was observed in the mice that consumed SPI, while fecal BA excretion remained unaltered. SPI also elicited dramatic changes in the gut microbiome, characterized by an expansion of taxa that may be involved in the biotransformation of BAs. The observed effects were abolished in germ-free (GF) mice, indicating that they were dependent on the microbiota. These findings collectively indicate that the metabolic benefits of SPI under the HFD regime may arise from a microbiota-driven increase in BA transformation and increase in GLP-1 secretion.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Competing Interests: All authors except three authors [T. Saito, T. Sato, and NT] have no conflict of interest. T. Saito, T. Sato, and NT are employees of Fuji Oil Co., Ltd., which is a manufacturer of food and food supplement including SPI.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0202083